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Abstract: This study used the Eri silk nanoparticles (NPs) for delivering apo-bovine lactoferrin 
(Apo-bLf) (~2% iron saturated) and Fe-bLf (100% iron saturated) in MDA-MB-231 and MCF-7 
breast cancer cell lines. Apo-bLf and Fe-bLf-loaded Eri silk NPs with sizes between 200 and 
300 nm (±10 nm) showed a significant internalization within 4 hours in MDA-MB-231 cells 
when compared to MCF-7 cells. The ex vivo loop assay with chitosan-coated Fe-bLf-loaded 
silk NPs was able to substantiate its future use in oral administration and showed the maximum 
absorption within 24 hours by ileum. Both Apo-bLf and Fe-bLf induced increase in expres-
sion of low-density lipoprotein receptor-related protein 1 and lactoferrin receptor in epidermal 
growth factor (EGFR)-positive MDA-MB-231 cells, while transferrin receptor (TfR) and TfR2 
in MCF-7 cells facilitated the receptor-mediated endocytosis of NPs. Controlled and sustained 
release of both bLf from silk NPs was shown to induce more cancer-specific cytotoxicity in 
MDA-MB-231 and MCF-7 cells compared to normal MCF-10A cells. Due to higher degree of 
internalization, the extent of cytotoxicity and apoptosis was significantly higher in MDA-MB-231 
(EGFR+) cells when compared to MCF-7 (EGFR-) cells. The expression of a prominent anti-
cancer target, survivin, was found to be downregulated at both gene and protein levels. Taken 
together, all the observations suggest the potential use of Eri silk NPs as a delivery vehicle for 
an anti-cancer milk protein, and indicate bLf for the treatment of breast cancer.
Keywords: breast cancer, silk nanoparticles, bovine lactoferrin, epidermal growth factor 
receptor, apoptosis
Introduction
With 12.7 million new cancer cases and 7.6 million cancer deaths in 2008 worldwide, 
cancer has become the leading cause of death in developing countries and the second 
leading cause of death in developed countries.1 Lung, prostate, breast, colorectal, and 
liver cancers are the most common types of cancers diagnosed every year. Breast cancer 
with 458,400 deaths, and colorectal cancer with 288,100 deaths in 2008 worldwide, 
became the leading types of cancer in females, whereas in males, the leading types 
of cancer were lung and bronchus cancer with 951,000 deaths, and liver cancer with 
458,000 deaths in the same year. Breast, prostate, and colorectal cancer are the most 
common types of cancers found in Australia and New Zealand.1
Though cancer is the leading cause of death worldwide, it has limited treatment 
options, including chemotherapy, radiation therapy, laser therapy, and surgery. Among 
all the treatments available, chemotherapy is the most commonly used cancer treatment, 
but it has severe side effects, as most of the chemotherapeutic drugs directly affect 
cell division and DNA synthesis. Common side effects of using chemotherapeutic 
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drugs include anemia, leukemia, fatal infections, immune 
system depression, nausea, vomiting, hair loss, fatigue, and 
many more.2
The “red fraction”, an undescribed protein from cow’s 
milk later on known as lactoferrin, was first identified in 
1939 by Sørensen and Sørensen.3 The same lactoferrin 
from human and bovine milk was defined as transferrin-like 
glycol protein in 1960.4 Initial studies revealed its biological 
role as anti-microbial, anti-viral, anti-fungal, anti-parasitic, 
anti-bacterial, and host defense immunomodulatory protein; 
also, its role in cell proliferation and differentiation was 
established.5–8 The concept of oral administration of bovine 
lactoferrin (bLf) was first introduced during 1978 when a 
bLf-containing dry milk was marketed by Morinaga Milk 
company in Japan.9 Later, the research and evidence indi-
cated the role of orally administered bLf by reporting the 
improvement in intestinal microbial flora, increased serum 
ferritin and hematocrit levels, reduction in lower respiratory 
tract diseases, and anti-infective activities.10–13
Work done in our laboratory over the years has estab-
lished bLf as an important anti-cancer natural therapeutic 
in different cancer models,14–16 and we have also developed 
an efficient nanoparticle (NP) system for cancer-specific 
delivery of bLf. We have shown that natural bLf and iron-
saturated forms of bLf (Fe-bLf) differ in their ability to 
augment cancer chemotherapy. By supplementing natural 
bLf (15% iron saturated), Apo-bLf (4% iron saturated), 
and 50% Fe-bLf into the diet of C57BL/6 mice that were 
subsequently challenged subcutaneously with tumor cells 
and were treated by chemotherapy, we found that Fe-bLf 
was a more potent natural adjuvant for augmenting cancer 
chemotherapy.17 A previous study from our laboratory18 has 
already established the anti-cancer activities of both Apo-bLf 
and Fe-bLf in MDA-MB-231 and MCF-7 cells. The results 
confirmed that the non-nanoformulated form of Apo-bLf 
induced significantly greater cytotoxicity and reduction in 
cell proliferation in both types of cancer cells. Most impor-
tantly it was also identified that key apoptotic molecules such 
as p53, Bcl-2, and survivin were significantly modulated by 
both forms of bLf.18
In another recent study,19 we determined the anti-cancer 
efficacy and the internalization mechanism of our ceramic 
NP system (calcium phosphate nanocores, enclosed in biode-
gradable polymers, chitosan and alginate, alginate-enclosed 
chitosan-coated calcium phosphate nanocarriers (NCs) 
loaded with Fe-bLf in breast cancer xenograft model). We 
confirmed that Fe-bLf NCs decreased tumor size by 4.8-fold 
compared to void NCs and prevented tumor recurrence 
when compared to doxorubicin and Taxol® intra-peritoneal 
injections. The key receptors facilitating the NCs’ internaliza-
tion (low-density lipoprotein  receptor related protein [LRP], 
lactoferrin receptor [LfR], and transferrin receptor [TfR]) 
were determined, and the micro-RNAs responsible for NC 
uptake were also identified.19
In the past 2 decades, the use of various types of NPs has 
yielded improved delivery of anti-cancer molecules to the 
tumor site. The most important benefit provided by the use 
of NPs is protection. Silk is mainly produced by cultured 
silkworms and several worms of the Lepidoptera family, 
including butterflies, and moths.20 Silks are high-molecular 
weight co-polymer like proteins with extraordinary mechani-
cal properties.21,22 Crucial properties of silk, including 
biodegradability, biocompatibility, environmental stability, 
morphologic flexibility, controlled release, and small particle 
size. Silk can be used in combinational therapy as it can eas-
ily undergo chemical modifications, it is docile to organic or 
aqueous solvent processing, and the ability to modify amino 
acids in side chains to immobilize any biological compound, 
have broadened its uses in biomaterials and in a wide range of 
biomedical applications.21,23 With extraordinary mechanical 
properties, naturally produced silk has gained much attention 
in past few years for its use in biomedical applications.24–27 
A study investigating the silk as a potential biomaterial for 
three-dimensional (3D) in vitro tumor modeling showed a 
better attachment and morphology of the MDA-MB-231 
cell line on Antheraea mylitta silk matrices.28 Eri silk is one 
such type of silk, which is very promising in producing a 
high quality silk powder with submicron particle size.29 This 
promising strategy of producing Eri silk with submicron 
particle size has generated an interest of using this silk as a 
drug delivery vehicle to target cancer.
The primary objective of the present study was to com-
pare the internalization of Eri silk (obtained from Samia 
cynthia ricini cocoons) NPs for delivering Apo-bLf and Fe-
bLf, and the activation of downstream apoptosis mechanism 
involved in two different breast cancer cell lines.
Materials and methods
silk NP preparation
Sodium carbonate, 2 g/L and sodium dodecyl sulphate, 
0.6 g/L (Sigma-Aldrich Co, St Louis, MO, USA) at 100°C 
were used for degumming Eri silk cocoons. Chopping, 
attritor milling, bead milling, and spray drying were the 
techniques used to prepare the powder from degummed Eri 
silk cocoons. The degummed silk was chopped into snippets, 
which were further wet-milled using an attritor (S-1; Union 
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Process, Akron, OH, USA) containing 5 mm zirconium oxide 
milling media. Attritor speed was 280 rpm. To get nano 
silk particles, attritor-milled slurry was processed through a 
bead mill (Willy A Bachofen AG Maschinenfabrik, Basel, 
Switzerland). Zirconium oxide grinding media (0.4–0.5 mm) 
were used in bead milling. A milling speed of 1,500–3,500 
rpm was used according to the manufacturer’s recommen-
dations. Cooling water (~18°C) was circulated through the 
milling chamber to minimize silk thermal degradation dur-
ing milling. The milled slurry-in-water was used for further 
experiments.29
The prepared silk NPs, were washed three times with 
sterile phosphate-buffered saline (PBS) and were sonicated 
for 3 minutes to remove the aggregation prior to use. The pH 
of silk NP suspension was adjusted to 7.2 prior to use. Fe-bLf 
and Apo-bLf were loaded on the silk NPs with 10% w/w ratio, 
as determined by a previous study done in our laboratory.30 
The mixture (silk NPs + Fe-bLf or silk NPs + Apo-bLf) was 
incubated for 48 hours with slow stirring (30 rpm) at 4°C. 
After 48 hours, the samples were collected and centrifuged 
at 1,500 rpm for 20 minutes. The supernatant was collected 
and stored, and the pellet was washed two times using sterile 
PBS to remove unbound Fe-bLf or Apo-bLf. The sample 
was then lyophilized using a Labconco Freeze Dryer. A 1% 
solution of Fe-bLf-loaded silk NPs and Apo-bLf-loaded silk 
NPs was prepared from the lyophilized powder to calculate 
the loading efficiency. Protein estimation was performed to 
determine the amount of Fe-bLf or Apo-bLf loaded onto silk 
NPs. The amount of protein (Fe-bLf and Apo-bLf) loaded 
on silk NPs was also confirmed from the protein estimation 
of supernatant collected after 48 hours of stirring.
NP characterization
A 0.1% solution of prepared NPs was made by diluting 
0.001 g of NPs in 1 mL of Milli-Q® water. The prepared 
0.1% solution was further diluted to 104 by serial dilution. 
Finally, the obtained NP solution was mixed well, and the 
particle size was analyzed by dynamic light scattering (DLS) 
using Malvern Mastersizer. Lyophilized NPs were gently 
placed and distributed on a carbon tube, which was placed 
on an aluminum-based scanning electron microscopy (SEM) 
stub. The samples were then gold coated in a sputter coater 
(Quorum Technologies Ltd, Laughton, UK) for 60 seconds 
to avoid charging of the samples. SEM was performed for 
all the NPs using a Supra™ 55 variable pressure electron 
microscope. NP samples were crushed finely in an agate 
mortar and pestle, were mixed with potassium bromide 
(KBr), and were finely ground. Finally, the mixture was 
placed into a pelletizer to form the KBr disc containing the 
sample. The KBr disc was then analyzed using a Bruker 
Fourier transform infrared (FTIR) Vertex 70 spectrophotom-
eter and Opus version 5.5 software (Bio-Rad Laboratories 
Inc, Hercules, CA, USA; Bruker Optics Inc, Billerica, MA, 
USA; Opus, Inc, Houston, TX, USA) in the wave number 
range of 400 to 4,000 cm-1.
rhodamine labeling of NPs
A 0.1% solution of Lissamine™ Rhodamine (Thermo Fisher 
Scientific, Waltham, MA, USA) was prepared to label a 1% 
solution of each NP. NPs and Rhodamine were mixed to 
make a total volume of 1 mL using Milli-Q in an Eppendorf 
tube® covered with aluminum foil. The tubes were placed on 
a rotor for 24 hours at 4°C for proper labeling of each NP. 
After 24 hours, the tubes were centrifuged, and the pellet was 
washed twice with PBS to remove the unbound Rhodamine; 
the pellet was then suspended in the treatment media prior to 
use. All steps related to Rhodamine labeling were performed 
in the dark to avoid loss of fluorescence.
cell line and culture conditions
The MDA-MB-231 and MCF-7 adherent epithelial cell lines 
were derived from the mammary gland of breast adenocarci-
nomas in humans, and breast epithelial cells MCF-10A were 
obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). ATCC guidelines were followed in 
maintaining these cell lines.
gel electrophoresis and Western blotting
Protein estimation results were used to calculate 80 µg 
(150 µg for cell lysate) of total protein per well. The samples 
were mixed with 10× sample buffer (with freshly added 
β-mercaptoethanol in a 1:10 ratio) and were allowed to heat 
at 95°C for 5 minutes. After loading the samples into each 
well, the gel (8%) was run at 200 V for 45 minutes using 
freshly prepared running buffer in a Mini PROTEAN® 3 gel 
tank (Bio-Rad Laboratories Inc). A protein standard marker 
(Bio-Rad Laboratories Inc) was used to compare the molecu-
lar weight of resulting bands from samples.
Using the Western blotting technique, proteins from a 
sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) gel were transferred onto polyvinylidene fluo-
ride (Amersham™ Hybond™ enhanced chemiluminescence; 
GE health care and life sciences, Australia) membrane. After 
probing the membrane using specific antibodies, it was dried 
and activated in dark using 1 mL total enhanced chemi-
luminescence detection system solution (GE Healthcare 
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Bio-Sciences, Pittsburgh, PA, USA) for 2 minutes. The 
membrane was then viewed using Bio-Rad ChemiDoc with 
an XRS Camera. Images were captured and processed using 
Quantity One software.
Internalization studies
To determine the NP internalization, the MDA-MB-
231 and MCF-7 cells were grown on eight-well slides 
in a 2×105 cells/mL concentration. When the cells were 
approximately 70%–75% confluent, they were treated with 
Rhodamine-labeled NPs for the time intervals of 4, 12, and 
24 hours. After treatment, media were removed and the cell 
layer was washed thoroughly using sterile PBS. Slides were 
then fixed using 4% paraformaldehyde (PF) for 20 minutes 
at 37°C followed by 3× wash with PBS. The cell layer was 
blocked with 3% bovine serum albumin for 30 minutes and 
post-washing, was incubated with primary antibody (goat 
anti-bLf; Bethyl Laboratories, Inc, Montgomery, TX, USA) 
1:100 for 1 hour. Post-washing, the cell layer was incubated 
with secondary fluorescein isothiocyanate (FITC)-conjugated 
antibody (anti-goat FITC; Sigma Aldrich Co) 1:100 for 
1 hour. The cells were washed again, and mounting medium 
with 4′6-diamidino-2-phenylindole (DAPI), Vectashield® 
(Vector Laboratories, Burlingame, CA, USA) was added to 
each well, and the slides were covered using 22×50 mm cover 
slips. Nail polish was used to seal the ends of the slide to 
prevent over-drying. Slides were then viewed under a Leica 
TCS SP5 confocal microscope, and images were taken and 
processed using Leica software, LASAF.
Omnizyme® in vitro digestion
The Omnizyme (human digestive enzyme cocktail), com-
mercially available proteolytic enzyme tablets, were pur-
chased from Rainrock Nutritionals (Newark, OH, USA). 
Omnizyme and Omnizyme forte® are potent blends of 
vegetable and animal sources of proteolytic, amylytic, and 
lipolytic enzymes, which also contain the important free 
radical-fighters superoxide dismutase and catalase. These 
tablets also contain the enzyme activator glutathione, as 
well as lyophilized calf thymus and zinc. The Omnizyme 
tablet was dissolved in 15 mL of 0.1 M NaHCo
3
 with a pH 
of 7.2. The samples (bLf-loaded NPs and plain bLf) and 
Omnizyme solution were mixed in the ratio of 1:50 and 
were incubated at 37°C at 200 rpm for the time intervals of 
2, 4, 6, and 24 hours. The samples were collected after each 
incubation time and were heated at 42°C for 5 minutes to 
stop the reaction. All the samples were run on an SDS gel 
for further analysis of digestion.31
Intestinal loop assay
The intestinal loop assay was performed as per a previously 
published protocol.32 Mice were sacrificed and intestines were 
removed by dissection. Duodenum, jejunum, and ileum sec-
tions were separated from each intestine and were incubated 
in sterile PBS. Each section of intestine was washed properly 
with PBS using a 23× G needle. One end of each section was 
tied using sterile thread, and Rhodamine-labeled NPs were 
injected from the open side. The open end was also tied 
after injecting the NPs, and the outer layer of the loop was 
washed in PBS. The loops were then incubated in six-well 
plates at 37°C with Roswell Park Memorial Institute (RPMI) 
1640 culture medium without phenol red, 10% fetal bovine 
serum, and 1.5% penicillin streptomycin. Equal amounts of 
media were collected from each well after the time intervals 
of 6, 12, and 24 hours. The same amount of fresh medium 
was supplemented each time. After 24-hour incubation, the 
loop was opened and all sections were properly washed with 
sterile PBS. The sections were then fixed with 4% PF over-
night, followed by freezing in optimum cutting temperature 
compound and storage at -80°C.33,34
histopathology
Using cryotome, sections of 10 µm were cut and placed 
on a slide. The sections were than fixed in 100% acetone 
for 20 minutes. The slides were air dried and were stained 
with hematoxylin and eosin (HE). Slides were incubated in 
hematoxylin for 6 minutes, followed by washing twice with 
fresh water. Acid alcohol for 2–3 seconds was used to remove 
excessive hematoxylin staining from the tissue samples. 
Slides were again washed with fresh water, and then they were 
incubated in eosin for 1 minute. After cytoskeletal staining 
using eosin, slides were again washed twice with fresh water 
and were allowed to dry. The sections were dehydrated in 
gradients of ethanol, 70%, 90%, and 100%, for 2 minutes 
each. The slides were completely dried after dehydrating and 
were mounted using normal mounting medium; 22×50 mm 
cover slips were used to cover the slides, and nail polish was 
applied to prevent over-drying. The tissue samples were then 
viewed under a microscope, and images were captured using 
a Zeiss axioscope 5 (Carl Zeiss Meditec AG, Jena, Germany) 
and modified using Adobe Photoshop. The slides were also 
viewed using the confocal microscope by adding DAPI.
cytotoxicity and apoptosis studies
A lactate dehydrogenase (LDH) assay was performed for 
cytotoxicity analysis as per the manufacturer’s instructions 
(cytotoxicity detection kit; Hoffman-La Roche Ltd, Basel, 
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Switzerland). After 24-hour treatments with silk NPs only, 
silk NPs + Apo-bLf, silk NPs + Fe-bLf, Apo-bLf only, and 
Fe-bLf only at a concentration of 3,200 µg/mL, the superna-
tant was collected. The optical density (OD) was measured 
at 492 nm, and percentage cytotoxicity was calculated. Cells 
were also treated and stained with annexin V (apoptosis 
marker) and propidium iodide (PI) (necrosis marker) as per 
the manufacturer’s instructions (annexin V assay; Thermo 
Fisher Scientific). The percentage population positive for 
annexin V or PI was determined using flow cytometry. 
Caspase-3 activity in the entire treatment group was measured 
using Acetyl-Asp-Glu-Val p-nitroanilide; Caspase-3 substrate 
was purchased from Sigma-Aldrich Co. The caspase activ-
ity was determined by following the directions given in the 
manufacturer’s instructions. Absorbance was measured at 
405 nm, and caspase-3 activity was calculated in mmol/mL 
concentration by using the following formula,
 
Caspase-3 
activity
(mM/mL)
OD at 405 nm  dilution factor (= × 100)
[E (mmol constant) time of incubation 
in minutes vol
×
× ume of sample]
 (1)
where value of the mmol constant is 10.5, incubation time is 
3 hours, and volume of the sample is the amount of sample 
added for loading 100 µg of the sample.
Tumor spheroid assay
Exactly 100 µL of 0.1% agarose solution was added in each 
well of 96-well plates. Once agar was solidified, 10³ (MCF-7 
and MDA-MB-231) cells/well were added to the plate and 
were incubated for 7 days at 37°C with 5% CO
2
. After 7 days, 
cells had formed nearly uniform spheroids in all the wells; 
the spheroids were treated for 24 hours with silk NPs only, 
silk NPs + Apo-bLf, silk NPs + Fe-bLf, Apo-bLf only, and 
Fe-bLf only at a concentration of 3,200 µg/mL. The surface 
area of tumor spheroids was measured using ImageJ software 
(US National institute of health [NIH], Bethesda, MD, USA), 
where the circumference tool was used to calculate the surface 
area in pixels, and the surface area was plotted as a graph.32
gene expression studies
TRIzol® reagent (Thermo Fisher Scientific), a ready-to-use 
reagent for total ribonucleic acid (RNA) isolation from cells, 
was used to isolate RNA from the viable cells after 12-hour 
treatments with silk NPs only, silk NPs + Apo-bLf, silk NPs + 
Fe-bLf, Apo-bLf only, and Fe-bLf only at a concentration of 
3,200 µg/mL in a six-well plate. SuperScript® III First-Strand 
Synthesis System for reverse transcriptase polymerase chain 
reaction (RT-PCR) (Thermo Fisher Scientific) was used for 
complementary DNA (cDNA) synthesis from isolated RNA. 
All the components required were supplied with the Super-
Script kit. Quantitative RT-PCR (qRT-PCR) iQ5 (Bio-Rad 
Laboratories Inc) was used for gene expression studies. An 
appropriate cycle was created in the software depending on 
the annealing temperature of individual primers.
Immunocytochemistry
The cells were cultured in eight-well slides with a concen-
tration of 2×105 cells/mL (250 µL/well). The treatment with 
silk NPs + Apo-bLf, silk NPs + Fe-bLf, and silk NPs only 
for 24 hours was done with an initial cell confluence of 80%. 
Silk NPs only and untreated cells were used as a control to 
check the effect of loaded protein. After each step, cells were 
washed three times with PBS. The treatment was removed 
after 24 hours, and the cell layer was washed with PBS fol-
lowing the fixing of the cells using 4% PF for 25 minutes. The 
cells were then permeabilized using 0.1% Triton™ X-100 for 
15 minutes by keeping the slide on ice. A 2% rabbit serum 
with 3% H
2
O
2
 (250 µL/well) was used as a blocking solution 
for 90 minutes. Goat primary antibody (1:100) against bLf 
(200 µL/well) was used to probe bLf for 2 hours, followed by 
incubation in the horseradish peroxidase-conjugated (1:100) 
secondary antibody (200 µL/well) for 1 hour. To visualize 
immunoreactivity, immunoperoxidase staining using 3,3 
Diaminobenzidine (DAB) substrate (Sigma-Aldrich Co) 
(100 µL/well) for 12 minutes was carried out. The slides 
were washed thoroughly after DAB staining with tap water 
and were mounted with permanent mounting medium.
statistical analysis
Significant differences between all treatment groups were 
determined by comparing individual treatments with 
untreated results using the Student’s t-test and Microsoft 
Excel. Results are presented with ± standard error of the mean 
(SEM). P-values #0.05 were considered as significant, and 
values of P#0.01 were considered to be highly significant.
Results
Physicochemical characterization of 
silk-loaded blf NPs
Apo-bLf and Fe-bLf were prepared from native bLf using the 
dialysis method, and their purity was detected by SDS-PAGE 
and Western blotting (Figure 1A [parts a, b, respectively]). 
DLS spectroscopy was used to determine the hydrodynamic 
size distribution profile of the NPs. Void silk NPs showed sizes 
ranging from 150 to 250 nm, whereas silk NPs loaded with 
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Figure 1 characterization of silk + blf NPs.
Notes: (A) Synthesis and purification of bLf forms was confirmed by (a) SDS-PAGE and (b) Western blotting. (B) DLS colorimetry confirmed the size of void NPs to be 
approximately 150–250 nm (a), while the silk + blf NPs (b) were 200–300 nm in size. (C) SEM confirmed an irregular shape (a, b and c); however, NPs were of uniform size. 
(D) sonication was used to prevent aggregation of (a) void, and (b) silk + blf NPs, as seen in microscopic images obtained at 20× magnification. (E) loading of blf in silk NPs 
was confirmed using Western blotting. (F) FTIR spectra revealed the presence of amide peaks, confirming the loading of bLf on silk NPs.
Abbreviations: NP, nanoparticle; bLf, bovine lactoferrin; Apo-bLf, apo-bovine lactoferrin; Fe-bLf, iron-saturated bovine lactoferrin; SDS-PAGE, sodium dodecyl sulphate 
polyacrylamide gel electrophoresis; DLS, dynamic light scattering; SEM, scanning electron microscopy; FTIR, Fourier transform infrared.
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silk nanoparticles as a delivery vehicle for bovine lactoferrin
Fe-BLf showed sizes ranging from 200 to 300 nm (Figure 1B 
[parts a, b, respectively]). SEM further confirmed the uniform 
size, morphology, shape, and pattern of the prepared NPs 
(Figure 1C). As Eri silk is known to aggregate11 in solvents 
at pH .5, sonication for 3 minutes was used to disaggregate 
the silk particles in PBS at pH 7.2 just before loading the bLf. 
Figure 1D shows microscopic images of the nanomaterial at 
40× magnification post-sonication, and these images depict 
loss of aggregation. Western blotting was performed to con-
firm the loading of bLf forms in silk NPs (Figure 1E). The peak 
at 1,269 cm-1 in the FTIR spectra represents the prominent 
α-helix structure.9 Amide-I linkage at 1,635 cm-1 showed no 
change in the secondary structure in silk particles, whereas 
change in the intensity of peak was because of high bind-
ing affinity between silk particles and Apo-bLf and Fe-bLf 
(Figure 1F). Proteins tightly bound with silk particles could 
result in sustained release of protein, with a higher amount of 
protein released at the tumor site or in cancerous cells.
receptor-mediated internalization of silk 
NPs in breast cancer cells
Confocal microscopy images reveal that void NPs failed to 
show substantial internalization in 4 hours in both MDA-MB-
231 and MCF-7 cells, but managed to internalize at 24 hours 
(Figure 2A). Both silk + Apo-bLf and silk + Fe-bLf NPs 
showed significantly higher internalization at 4 and 24 hours 
in MDA-MB-231 cells, while only silk + Apo-bLf managed 
to show significant internalization in MCF-7 cells. In order 
to decipher the internalization patterns in these cells, qRT-
PCR was performed to determine the expression of LRP1, 
LRP2, LfR, TfR, TfR1, and TfR2 in both MDA-MB-231 and 
MCF-7 cells (Figure 2B). It was found that MDA-MB-231 
cells showed significantly higher expression of LRP1, LRP2, 
LfR, and TfR1 with silk NP treatments, while MCF-7 cells 
showed an increase in TfR and TfR2 receptor expression 
with treatments of silk NPs. This result confirmed that NPs 
internalized more in MDA-MB-231 cells due to the expres-
sion of more surface receptors.
Delivery of apo-blf and Fe-blf in 
MDa-MB-231 cells
Void silk NPs were not able to internalize efficiently into cells 
after 12 hours. bLf-specific immuno-reactivity was observed 
as green (FITC) fluorescence in Figure 3A, which confirms the 
co-localization of Apo-bLf loaded on the silk NPs, as well as 
the presence of released protein in the cytoplasm and near the 
nucleus of the cells. Within 12 hours, Apo-bLf-loaded silk NPs 
were able to efficiently carry and release the loaded Apo-bLf 
into the cells. Yellow fluorescence (green + red) in the merged 
images of Figure 3A shows the detection of Apo-bLf loaded 
on silk NPs by the bLf-specific antibody. NPs were seen to 
be taken up by all MDA-MB-231 cells, with a maximum 
co-localization of NPs in the nucleus and cytoplasm of cells. 
Observations showing the fragmentation and distortion of 
cell layers and nuclei demonstrated the significantly high 
cytotoxic and anti-cancer effect of silk NPs loaded with Fe-bLf 
on MDA-MB-231 cells. Western blot analysis from protein 
lysates indicated the presence of bLf after 12 hours’ treat-
ment in MDA-MB-231 cells (Figure 3B). This result further 
proved the internalization of NPs in both MDA-MB-231 and 
MCF-7 cell lines, as studied using confocal microscopy. The 
images after the 24-hour treatment also revealed that NPs were 
internalized in MDA-MB-231 cells and induced cytotoxicity, 
while very low cytotoxicity could be observed in MCF-7 cells, 
as most NPs failed to internalize (Figure 3C).
Protection of blf from enzymatic 
degradation and increased intestinal 
uptake
Digestion of bLf protein was confirmed using commer-
cially available Omnizyme tablets. Unloaded Apo-bLf 
and Fe-bLf, and silk NPs loaded with Apo-bLf and Fe-
bLf, were tested for digestion at different time intervals 
(Figure 4A [parts a, b]). That bLf forms loaded on silk 
NPs were digested by Omnizyme is probable, because it 
is not protected with any outer covering layer, and hence, 
it is directly available to the digestive enzyme. Compared 
to only protein, silk NP-loaded proteins were less digested, 
as bLf was strongly bound to NPs. Equal amounts of 
protein were loaded in each well to check the amount of 
digestion by Omnizyme. The maximum digestion of free 
and loaded bLf was observed after 24 hours of incubation 
with Omnizyme. After 6 hours, Rhodamine-labeled NPs 
were co-localized mainly in serosa, mucosal layers, and 
sub-mucosal layers of the ileum, as indicated by arrows 
(Figure 4B). NPs were also localized in the intestinal gland, 
crypt, and plicae circulares portion of the ileum. Hema-
toxylin and eosin staining confirmed the intact structure 
of ileum and mucoadhesion after 6 hours of incubation 
with Fe-bLf-loaded silk NPs (Figure 4C). The presence of 
bLf in various segments of intestinal tissue was confirmed 
by Western blotting, suggesting that silk NPs led to an 
enhanced uptake of bLf (Figure 4D).
blf-loaded silk NP induced apoptosis in 
breast cancer cells
LDH assay results confirmed that bLf-loaded silk NPs led 
to specific cytotoxicity in MDA-MB-231 cells. Void silk 
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Figure 2 Internalization efficacy of silk + blf NPs in breast cancer cells.
Notes: (A) Confocal images revealed that void NPs failed to significantly internalize in both MDA-MB-231 and MCF-7 cells. Silk + apo-blf showed comparatively higher internalization 
than silk + Fe-bLf in both MDA-MB-231 and MCF-7 cells. However, MDA-MB-231 cells showed significantly higher uptake of NPs than MCF-7 cells. (B) The gene expression of 
receptors revealed enhanced expression of lrP1, lrP2, lfr, and Tfr1 in MDa-MB-231 cells, while only Tfr1 and Tfr2 were found to be upregulated in McF-7 cells.
Abbreviations: DaPI, 4′6-diamidino-2-phenylindole; NPs, nanoparticles; bLf, bovine lactoferrin; Apo-bLf, apo-bovine lactoferrin; Fe-bLf, iron-saturated bovine lactoferrin; 
LRP, lipoprotein receptor-related protein; LfR, lactoferrin receptor; TfR, transferrin receptor.
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silk nanoparticles as a delivery vehicle for bovine lactoferrin
NPs failed to induce significant cytotoxicity in primary 
(MCF-10A) as well as cancerous breast cells (MDA-MB-
231, MCF-7) (Figure 5A). Nano-free forms of Apo-bLf and 
Fe-bLf showed significant cytotoxicity in both MDA-MB-
231 and MCF-7 cells (88% and 72% apoptosis for Apo-
bLf, respectively; and 79% and 78% apoptosis for Fe-bLf, 
respectively), while silk + Apo-bLf and silk + Fe-bLf forms 
induced significant cytotoxicity in only MDA-MB-231 cells 
(92% apoptosis for silk + Apo-bLf and 83% apoptosis for 
Fe-bLf). Annexin V assay was done to confirm apoptosis in 
treated breast cancer cells (Figure 5B). The results revealed 
that for MCF-7 cells, Apo-bLf led to only 36% apoptosis, 
while silk + Apo-bLf led to relatively higher apoptosis 
(47%), which was higher than for Fe-bLf only (26%) and 
Fe-bLf + silk (14%). For MDA-MB-231 cells, a similar 
trend was observed, where Apo-bLf only (50% apoptosis) 
and Apo-bLf + silk (52% apoptosis) led to higher apoptosis 
when compared to Fe-bLf only (28% apoptosis) and Fe-bLf + 
silk (33.5% apoptosis). Expression of caspase-3, which is the 
final activator of apoptosis, was detected by caspase-3 assay 
(Figure 5C). All treatments failed to induce any significant 
increase in caspase-3 expression in MCF-10A cells. It was 
observed that both Apo-bLf only and Fe-bLf only induced 
significantly higher caspase-3 expression in MDA-MB-231 
cells (26% [P,0.05] and 28% [P,0.05], respectively) and 
in MCF-7 cells (17% and 24% [P,0.05], respectively). 
However, silk + Apo-bLf induced higher caspase-3 expres-
sion in MDA-MB-231 and MCF-7 cells (37.5% [P,0.01] 
and 30.1% [P,0.05], respectively) when compared to silk + 
Fe-bLf (25% [P,0.05] and 18%, respectively).
The results from multicellular tumor spheroid assay 
revealed that only silk NPs did not lead to any significant 
decrease in the size of tumor spheroids, while only Apo-
bLf led to a 2-fold reduction in spheroid size (P,0.01) 
in both MCF-7 and MDA-MB-231 cells. Only Fe-bLf 
led to 1.7-fold reduction in tumor spheroid size in MDA-
MB-231 cells (P,0.01), but only 1.23-fold reduction in 
MCF-7 cells. Silk NPs + Apo-bLf and silk NPs + Fe-bLf 
led to a significant reduction (1.8-fold [P,0.0] and 1.5-fold 
[P,0.05], respectively) in MDA-MB-231 cells (Figure 5D). 
However, both treatments failed to induce significant effects 
in MCF-7 cells.
Figure 3 silk NPs successfully delivered blf into cells, inducing anti-cancer activity.
Notes: (A) The confocal microscopy images confirmed the presence of Apo-bLf and Fe-bLf (green) delivered by silk NPs (red) in the breast cancer cells (MDA-MB-231) 
within 12 hours. (B) Western blotting using the cell lysates also confirmed the presence of bLf forms in MDA-MB-231 cells. (C) The images from inverted microscopy 
revealed the presence of NPs in the media in McF-7 cells, while most NPs were internalized by the MDa-MB-231 cells.
Abbreviations: DaPI, 4′6-diamidino-2-phenylindole; NPs, nanoparticles; bLf, bovine lactoferrin; Apo-bLf, apo-bovine lactoferrin; Fe-bLf, iron-saturated bovine lactoferrin; 
LRP, lipoprotein receptor-related protein; LfR, lactoferrin receptor; TfR, transferrin receptor.
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Figure 6 gene and protein expression of key apoptotic markers.
Notes: (A) Genes were amplified using qRT-PCR iQ5, and graphs were plotted by calculating 2-∆∆ct. (B) Immunocytochemistry for MDa-MB-231 cells treated with (a) untreated 
cells as a control, (b) silk NP only-treated cells, (c) silk NP + Fe-blf-treated cells, and (d) silk NP + apo-blf-treated cells. (C) Western blotting assay to determine the effect of 
silk NPs + blf on expression of egFr, Bcl-2, and survivin. (D) Band density analysis for Western blots revealed that silk NPs + Fe-blf was he most effective treatment. lane 1, 
untreated; lane 2, silk NP only treated; lane 3, Apo-bLf only treated; lane 4, Fe-bLf only treated; lane 5, silk NPs + Apo-bLf treated; and lane 6, silk NPs + Fe-blf treated.
Abbreviations: EGFR, epidermal growth factor receptor; Bcl, B-cell lymphoma-2; qRT-PCR, quantitative real-time polymerase chain reaction; NPs, nanoparticles; bLf, 
bovine lactoferrin; Apo-bLf, apo-bovine lactoferrin; Fe-bLf, iron-saturated bovine lactoferrin; LRP, lipoprotein receptor-related protein; LfR, lactoferrin receptor; TfR, 
transferrin receptor; BAX, Bcl-2-associated X protein; Fas, death receptor; Fas-L, Fas-ligand death receptor.
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gene and protein expression for key 
apoptotic markers
qRT-PCR results (Figure 6A) revealed that bcl-2-like 
protein 4 (BAX), a pro-apoptotic effector protein of the Bcl-2 
family responsible for permeabilizing the mitochondrial 
membrane during apoptosis, was observed to be upregulated 
in MDA-MB-231 cells (Figure S1). The significant upregula-
tion of BAX was shown in MCF-7 cells after treatment with 
silk NPs loaded with Apo-bLf (Figure S2). In addition, the 
inner mitochondrial membrane protein, cytochrome C, was 
also upregulated in both MDA-MB-231 and MCF-7 cell 
lines. Caspase-9, an apoptotic gene of the caspase cascade, 
regulates via the intrinsic pathway; this gene was upregulated 
by 26-fold with non-formulated Apo-bLf treatment, and was 
18-fold increased with nanoformulated Fe-bLf treatment of 
MDA-MB-231 cells. Caspase-9 was unaffected by silk + 
Fe-bLf, but was downregulated in all other treatments in 
MCF-7 cells, as shown in Figures 6A and S2. Caspase-8, an 
apoptotic gene of the caspase cascade regulated via extrinsic 
pathway, was upregulated in MCF-7 cells, whereas slight 
variation in gene expression of caspase-8 was observed in 
MDA-MB-231 cells. Caspase-3 and caspase-7, effector cas-
pases from caspase family proteins, were upregulated in both 
MDA-MB-231 and MCF-7 cells with all the treatments, and 
significant upregulation was observed in silk NPs loaded with 
both forms of bLf. MDA-MB-231 and MCF-7 cells, when 
treated with 3,200 µg/mL of Apo-bLf and Fe-bLf alone, as 
well as after loading on silk NPs, showed downregulation of 
anti-apoptotic gene B-cell lymphoma-2 (Bcl-2) and survivin, 
and upregulation in apoptotic genes BAX, caspase-9, cas-
pase-8, and caspase-3, which were involved in both apoptotic 
pathways. The death receptors, Fas and Fas-Ligand (Fas-L) 
of the extrinsic pathway, were upregulated in MCF-7 cells 
but were downregulated in MDA-MB-231 cells. Expression 
of tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand (TRAIL) was also upregulated in both cell lines when 
treated with both the forms of bLf-loaded silk NPs. Immu-
noperoxidase staining results showed the maximum cytotoxic 
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
37
silk nanoparticles as a delivery vehicle for bovine lactoferrin
effect of silk NPs loaded with Fe-bLf after 24 hours in MDA-
MB-231 cells (Figure 6B). Most of the cells were found dead, 
and the remaining cells were highly apoptotic, as confirmed 
by distorted nuclei and ruptured cytoplasm. On the other 
hand, 24 hours’ treatment with silk NPs loaded with Apo-bLf 
was also observed to act against MDA-MB-231 cells, but 
the effect was less than from silk NPs loaded with Fe-bLf. 
A highly-colored brown reaction indicated the accumulation 
of Apo-bLf-loaded NPs in the cytoplasm and nuclei of the 
cells. This observation indicated that the protein was still 
available on the NPs and had not been utilized completely, 
hence indicating the efficiency of NPs to effectively protect 
and deliver Apo-bLf and Fe-bLf to MDA-MB-231 cells. 
Western blotting (Figure 6C) was performed to determine 
the expression of key apoptotic markers in MDA-MB-231 
cells. Slight downregulation in EGFR was seen by Apo-bLf 
treatment (1.4-fold), whereas Fe-bLf and silk NPs + Apo-
bLf did not show any downregulation in EGFR expression at 
protein level. Silk NPs + Fe-bLf were found to be the most 
effective in downregulating EGFR (5-fold downregulation). 
A significant downregulation in the expression of survivin 
was observed with Fe-bLf (2.5-fold) and silk NP + Fe-bLf 
(7-fold). Bcl-2 was also seen to downregulate with silk NP + 
Fe-bLf treatment (11-fold downregulation), but silk NP and 
Apo bLf treatments led to an increase in Bcl-2 expression 
(Figure 6D).
Discussion
Breast cancer, being one of the major and significant dis-
eases in Western countries, affects one out of nine women 
in Australia.35 To eradicate breast cancer completely, non-
toxic, safe, non-invasive, and highly effective treatment is 
needed. Various anti-cancer peptides/proteins, including 
arginine-glycine aspartate peptide and antagonists to anti-
apoptotic genes such as survivin antagonists, have been 
shown to boost anti-tumor effects and therapy. Quick renal 
clearance is one of the major hurdles faced while using 
these molecules in humans and rodents.30,36 Considering its 
anti-cancer properties, natural availability, and its immune-
modulation and immune-enhancing capacities, bLf is one 
of the ideal proteins that can be used to achieve maximum 
anti-cancer effects, without causing any toxicity to sur-
rounding normal cells and tissues. Various studies on bLf, 
a natural milk protein, have proved its anti-cancer effects 
and lack of toxicity to normal cells.15,30,37 In addition to its 
natural immune-modulation capacity,17,40 bLf has also been 
shown to have immune-enhancing and anti-carcinogenic 
properties, because it can reduce chemically induced tumors 
in rats and humans.17,37,41–42 The key findings of the current 
investigation suggest the efficient role of Eri silk NPs in car-
rying anti-cancer bLf proteins and inducing apoptosis using 
mitochondrial/intrinsic pathway of apoptosis.
Reports suggest that the internalization of bLf is 
facilitated by either TfR or LRP receptors.18,30,35,42–44 Silk 
NPs alone were not able to internalize into the cells, even 
after 24 hours of incubation, whereas bLf-loaded silk NPs 
internalized within 2 hours. A previous study has shown 
that, generally, the silk polymer must be complexed with 
other polymers such as fibroin, and must be coated with 
ligands to increase internalization potential of NPs.45 These 
findings generated our interest to look for the downstream 
mechanism and the receptors involved in the internalization 
of bLf-loaded silk NPs. qRT-PCR studies performed for 
the first time with Eri silk NPs loaded with bLf showed the 
significant upregulation of LRP1 in MDA-MB-231 cells, 
whereas no significant change in the expression of LRP1 
was seen MCF-7 cells. TfRs including both TfR1 and TfR2 
receptors did not show significant difference in treatments 
when compared to untreated and silk NP-treated MDA-MB-
231 cells, suggesting the involvement of LRP1-, LRP2-, 
LfR-, and TfR1-mediated internalization of silk NPs loaded 
with bLf. In MCF-7 cells, TfR1 and TfR2 expression was 
significantly upregulated with silk NPs loaded with Fe-bLf 
treatment. Fas and Fas-L, responsible for the activation of 
the extrinsic pathway, were downregulated in MDA-MB-231 
cells and upregulated in MCF-7 cells when treated with silk 
NPs loaded with both forms of bLf.
The results from the Omnizyme treatment confirmed that 
bLf forms in silk NPs showed comparatively higher resis-
tance to Omnizyme when compared to non-nanoformulated 
bLf forms. A previous study from our laboratory has shown 
that bLf forms are prone to Omnizyme degradation; however, 
upon degradation, they give rise to a large C-lobe fragment 
(51 kDa), a small N-lobe fragment (36 kDa), and product 
fragments of non-homologous cleavage (~kDa).46 Similar 
findings were observed in the present study, confirming that 
our findings are in accordance with the published reports.
The results of the ex vivo loop assay in the current study 
suggest the suitability of loaded bLf protein for absorption 
in various parts of the intestine, because of the presence of 
receptors in different parts of the intestine.33,34 Western blot 
analysis illustrated that Fe-bLf loaded on silk NPs was pres-
ent in the intact form after it was absorbed from the intestinal 
loops. This result showed the binding affinities of silk and bLf 
protein, as well as the ability of the Eri silk NPs to carry and 
successfully deliver the loaded bLf protein by maintaining 
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the intactness of bLf. The confocal microscopy images from 
6-hour incubated ileum sections showed the absorption of silk 
NPs loaded with Fe-bLf by villi and co-localization in serosa, 
mucosal layers, and sub mucosal layers of the intestine.
Eri silk, being a biodegradable and biocompatible protein, 
showed no effect on MCF-10A, MDA-MB-231, and MCF-7 
cells when administered alone. This result demonstrated the 
non-toxicity of Eri silk NPs to cells. Even though a previous 
publication from our lab suggested that Apo-bLf had higher 
cytotoxicity in both MDA-MB-231 and MCF-7 cells,18 our 
current findings reveal that since silk NPs failed to signifi-
cantly internalize in MCF-7 cells, cytotoxicity induced by 
both silk NPs + Apo-bLf or silk NPs + Fe-bLf in MCF-7 
cells was lower than in MDA-MB-231 cells. It was also 
observed in our present study that Apo-bLf induced more 
apoptosis in both MCF-7 and MDA-MB-231 cells when 
compared to Fe-bLf. 
Along with LRP1 receptors in MDA-MB-231 cells, 
EGFR and TRAIL expression were also upregulated with 
silk NPs loaded with bLf treatment. Similar upregulation in 
the expression of TRAIL was also observed in MCF-7 cells. 
EGFR is the most prominent transmembrane receptor that is 
responsible for the activation of series of intracellular path-
ways.47 A study investigating DAB dendrimers in nanosys-
tems showed that an upregulation in the expression of EGFR 
in human alveolar epithelial cell line A549 was responsible 
for uptake of dendrimers.48 In the present study, we found 
that EGFR+ MDA-MB-231 cells showed higher expression 
of LRP and LfR receptors compared to EGFR- MCF-7 cells, 
which led higher uptake of silk + bLf NPs in MDA-MB-231 
cells, and thus, more apoptosis and cytotoxicity in them when 
compared to MCF-7 cells (Figure 7).
The final outcome of any treatment is based on the capac-
ity of the drug to induce apoptosis of the cancer cells. As 
bLf is known to activate the intrinsic pathway of apoptosis 
in oral carcinomas,49 out current observations showing the 
downregulation of Bcl-2, an anti-apoptotic protein, the 
increase in cytochrome C (inner membrane protein), and 
Figure 7 silk + blf NPs induced apoptosis in egFr +ve and egFr -ve cells. 
Notes: Internalization of both forms of nanoformulation was facilitated via lrP1 receptors and egFr in MDa-MB-231 cells and via death receptors in McF-7 cells. In 
MDa-MB-231 cells, downregulation of anti-apoptotic genes and upregulation of apoptotic genes activated the intrinsic/mitochondrial pathway of apoptosis. In McF-7 cells, 
apoptosis was mediated through upregulation of death receptors (Fas and Fas-l), caspase-8, and caspase-3 and -7, along with the upregulation in BaX. Black arrows in the 
figure show the upregulation and downregulation in gene expression. “Hybrid” denotes the formation of lyso-endosome (lysosome + endosome). Protein from NPs was 
released slowly inside the cells, and the unwanted materials, including NPs and receptors, were expunged by the cells via exocytosis. red arrows are the signalling mechanism 
while black arrows are the effect of blf on individual proteins/markers denoting upregulation or downregulation.
Abbreviations: IAPs, inhibitors of apoptosis proteins; EGFR, epidermal growth factor receptor; Bcl, B-cell lymphoma-2; NPs, nanoparticles; bLf, bovine lactoferrin; Apo-bLf, 
apo-bovine lactoferrin; Fe-bLf, iron-saturated bovine lactoferrin; LRP, lipoprotein receptor-related protein; LfR, lactoferrin receptor; TfR, transferrin receptor; BAX, Bcl-2-
associated X protein; Fas, death receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
0&)FHOO(*)5±
6LON$SRE/I)HE/I13V
)DV)DVOLJDQG&HOOPHPEUDQH (QGRVRPH
(QGRVRPH
(QGRF\WRVLV
75$,/
(QGRF\WRVLV
+\EULG
+\EULG
5HOH
DVH
G
SURW
HLQ
5HOHDVHGSURWHLQ
&DVSDVH
&DVSDVH
$SRSWRVLV
&\WRFKURPH&UHOHDVHG
&\WRFKURPH&
%FOIDPLO\$QWLDSRSWRWLF%$;IDPLO\3URDSRSWRWLF ,$3IDPLO\SURWHLQ
&DVSDVH
&DVSDVH
$SRSWRVLV
6XUYLYLQ
8SUHJXODWLRQ
'RZQUHJXODWLRQ
/\VRVRPH
0'$0%FHOO(*)5
6LON$SRE/I)HE/I13V
$FWLYDWHG/53UHFHSWRU
(*)5
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39
silk nanoparticles as a delivery vehicle for bovine lactoferrin
the upregulation of BAX, a pro-apoptotic protein, illustrate 
the activation of the intrinsic pathway of apoptosis in 
MDA-MB-231 cells when treated with silk NPs loaded with 
both forms of bLf. Apo-bLf, when used in non-nano-form, 
showed better anti-cancer effects compared to Fe-bLf in 
non-nano-form in MDA-MB-231 cells, but nanoformulated 
Fe-bLf showed better anti-cancer effects compared to any 
other form of treatment. In MCF-7 cells, no change in the 
genes involved in the intrinsic pathway was observed, except 
an increase in cytochrome C, which could be the result of loss 
of mitochondrial potential as cells go under apoptosis. The 
upregulation in caspase-8 in MCF-7 cells showed that apop-
tosis was mediated via activation of the extrinsic apoptotic 
pathway. Western blotting results were also in accordance 
with a previous study in which we found that both forms of 
bLf (Apo-bLf and Fe-bLf) led to downregulation of Bcl-2 
and survivin.18 Hence, our current findings confirm that bLf, 
when delivered using silk NPs, forms an efficient system to 
induce apoptosis in EGFR + ve breast cancer cells.
Conclusion
Successfully developed low particular size Eri silk NPs have 
a strong binding and loading ability for Apo-bLf and Fe-bLf. 
Silk NPs loaded with each of the forms of bLf were able 
to induce anti-cancer activity in both MDA-MB-231 and 
MCF-7 cell lines using different internalization and apopto-
sis mechanisms. The internalization studies and qRT-PCR 
results indicated, for first time, that Eri silk NPs loaded with 
Fe-bLf protein may be used for the treatment of breast cancers 
with EGFR, LRP, and TfR receptor expression. Fe-bLf, when 
used in nanoformulation, activated the intrinsic pathway of 
apoptosis by significant downregulation of anti-apoptotic 
molecules including survivin and Bcl-2, and by upregula-
tion of pro-apoptotic and apoptotic genes such as BAX and 
caspases in MDA-MB-231 cells. The same nanoformulations 
were observed activating the extrinsic pathway and intrinsic 
pathway of apoptosis in MCF-7 cells. The maximum absorp-
tion of silk + Fe-bLf in the ileum and the intact structure of 
gut and villi suggest the use of Eri silk NPs in near future for 
further in vivo studies. Also, the ex vivo loop assay further 
suggests the use of chitosan-coated Eri silk NPs for oral 
administration. The outcome from the present study clearly 
indicates the role of bLf as a strong and promising therapeutic 
agent for breast cancer.
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Figure S1 Fold change in gene expressions for MDa-MB-231 cells.
Note: representative analysis for quantitative Pcr analysis of key apoptotic markers and lactoferrin receptors.
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Figure S2 Fold change in gene expressions for McF-7 cells.
Note: representative analysis for quantitative Pcr analysis of key apoptotic markers and lactoferrin receptors.
1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I 1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I
1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I 1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I
0&)
±¨¨
&W
±¨¨
&W
±∆∆
&W
±∆∆
&W
)DV
/53
)DV/
/53







±






± ±







±




1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I 1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I
1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I 1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I
1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I 1RWUHDWPHQW 6LON13VRQO\ $SRE/IRQO\ )HE/IRQO\ 6LON$SRE/I 6LON)HE/I
0&)
±∆∆
&W
±∆∆
&W
±∆∆
&W
±∆∆
&W
±∆∆
&W
±∆∆
&W
/I5 7I5
7I5 7I5
(*)5 75$,/






±
±±
 





±


















±
